Tumori, da Silva (Gilead): "In Italia 2mila donne trattate con sacituzumab govitecan"

1 year ago

(Adnkronos) - “Tre anni fa siamo entrati nell’area dell’oncologia solida e con un innovativo farmaco-anticorpo coniugato” sacituzumab govitecan “abbiamo già aiutato a trattare circa 2 mila donne in Italia con tumore al seno metastatico triplo negativo (mTnbc). Oggi celebriamo due traguardi: la nuova indicazione del farmaco per il tumore al seno metastatico Hr positivo, che in Italia colpisce circa 6-8 mila donne ogni anno, e l'estensione dell'indicazione” in seconda linea “al tumore al seno triplo negativo, quello più aggressivo”. Così Frederico da Silva, amministratore delegato di Gilead Sciences Italia, all’incontro con la stampa dedicato all’estensione di indicazione del farmaco anticorpo-coniugato nel tumore al seno metastatico Hr+/Her2 e in seconda linea nel triplo negativo.

Transcript

00:00Our mission from the beginning, from the age of 35, is really to revolutionize the courses of care for serious diseases.

00:10We have done it in HIV, we have done it in hepatitis, in COVID, but also in oncology and mato-oncology.

00:16Now, for three years, also in oncology.

00:19We have arrived with a therapy, a truly innovative antibody drug conjugate,

00:23to the triple negative metastatic tumor.

00:27With that, we have already helped to treat about 2,000 women in Italy,

00:33but obviously this path continues with what we are announcing today,

00:37but it will also continue in the future, because we also want to continue to strengthen our commitment in this area of solid oncology.

00:43We currently have about 30 clinical studies globally, 15 here in Italy,

00:50we do a lot of research, and we hope to arrive by 2030 with 29 indications,

00:56both in the breast tumor, as well as in the lung tumor, genitourinary, and other types of tumors.

01:03Today we celebrate a new milestone for two.

01:06The first is the new extension, or the new indication, I would say, in the HIV-positive metastatic breast tumor.

01:12There are about 6,000-8,000 women who face this type of metastatic breast tumor every year in Italy,

01:18and now we can also arrive with a new innovative technology to help its treatment path,

01:26trying to give more life and also more quality of life to the second.

01:29And the extension of the indication in the triple negative breast tumor, the most aggressive one,

01:35now for the entire second line, also women who progress more quickly in their disease.

01:42We know that in this setting the temporal response and temporal intervention are important.

01:47However, if you allow me, I wanted to say that it is really a very important milestone.

01:52I want to thank the scientific community, the Association of Patients, the institution,

01:57and all those who have collaborated to get to this point.

02:01A job that is not finished, because now there is the whole component of regional access.

02:06I hope that here too we can go fast to be able to really bring benefits to all women who can benefit.

Tumori, da Silva (Gilead): "In Italia 2mila donne trattate con sacituzumab govitecan"

Category

Transcript

Comments

Recommended